21m
PTC Therapeutics Shares 24-Month Votoplam Data Showing Dose-Linked Huntington’s Slowing Signals
PTC Therapeutics (NASDAQ:PTCT) reported top-line results from a 24-month interim analysis of the PIVOT-HD long-term extension (LTE) study evaluating Votoplam in Huntington’s disease, highlighting what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results